CELL AND GENE THERAPY CHALLENGES

Products and services for complex cell and gene therapy environments

Throughout the cell and gene therapy development cycle, there are common challenges that arise. The right partner can help clear the path for your breakthrough cell and gene therapies.

Azenta_Overview_IncreasingChallenges_Image
Chart - Overview

SCALING UP

Rigor and reproducibility are essential as therapies advance toward approval.

Question - Overview

PROTOCOL AMBIGUITY

Inadequately defined protocols for emerging and existing therapies can lead to roadblocks.

Sample Management - Overview

SAMPLE MANAGEMENT

Cold Chain logistics and storage challenges complicate clinical trials and manufacturing.

CAPABILITIES VIDEO

Your CGT vision is now

within reach

azenta life sciences cell and gene therapy video

ELEVATE YOUR SCIENCE

Transcend expectations

See how Azenta Life Sciences can help you address challenges proactively to mitigate risk and accelerate development.
download infographic
Azenta_Overview_Elevate_04

GLOBAL STORAGE LOCATIONS & LOGISTICS NETWORK

From cell banks to cGMP materials and finished products, our trained staff and certified facilities specialize in cold chain storage and management and provide a fully documented audit trail.

Azenta_Overview_Elevate_01

AUTOMATED STORAGE SOLUTIONS

Solutions and expertise including cryogenic, supporting detailed inventory tracking, and reporting capabilities.

Azenta_Overview_Elevate_02-1

PROPRIETARY GENOMICS PROTOCOLS

Customers rely on our proprietary hairpin and GC-rich protocols to synthesize and sequence long and difficult DNA sequences with trusted results.

 

Azenta_Overview_Elevate_03

INDUSTRY EXPERTS

We will guide you through common challenges of advanced therapy development.

COMPREHENSIVE SOLUTIONS

Preparing for scalable

CGT solutions

Azenta Life Sciences provides a comprehensive range of solutions across every phase of CGT development. We'll support the rigor of your program all the way from target discovery through scale-out.

 

Discovery

TARGET DISCOVERY | LEAD GENERATION & CHARACTERIZATION

 

Preclinical & Clinic

VECTOR & CELL BANK CONFIRMATION | CLINICAL TRIALS

 

Manufacturing & Distribution

MANUFACTURING SCALE-UP | THERAPEUTICS MANAGEMENT

Next-Generation Sequencing
Next-Generation Sequencing
 
Synthetic DNA Solutions
 
 
Sanger Sequencing
Sanger Sequencing
Sanger Sequencing
Automated Storage and Cold Chain Product
Automated Storage and Cold Chain Product
Automated Storage and Cold Chain Product
Sample and Material Storage Solutions
Sample and Material Storage Solutions
Sample and Material Storage Solutions
Digital PCR (dPCR)
Digital PCR (dPCR)
 

PATIENT IMPACT

How the Whitehead family continues the fight against childhood cancers

In 2010, Emily Whitehead was diagnosed with lymphoblastic leukemia. Just five-years old, she received chemotherapy - the best available treatment at the time. When her cancer returned in 2011, Emily became the first child in the world to receive an experimental CAR T-cell therapy.

MONTHLY WEBINAR

Join Us for Bridging the Gap

 

A monthly panel discussion on emerging topics that are changing the field of cell and gene therapy 

Co-sponsored by the Emily Whitehead Foundation with prominent guests and hosts from hospitals, treatment centers, and the cell and gene therapy industry.

STAY IN TOUCH

Be among the first to learn what's newly possible

Want to validate, optimize, or scale up right now? Need to know what's next? Connect with Azenta Life Sciences, leading the way in CGT infrastructure and expertise.